Highlights•Peripheral artery disease (PAD) is characterized by increased cardiovascular
risk.•Statins remain the first-line lipid-lowering therapy to treat PAD patients.•Statins …

Peripheral artery disease (PAD) is estimated to affect approximately 8.5 million individuals in
the US above the age of 40, and is associated with significant morbidity, mortality, and …

Abstract Purpose of Review There is a lack of consistency among the ACC/AHA and ESC
Guidelines on the treatment of patients with lower extremity PAD to a targeted LDL-c level. A …

Peripheral arterial disease (PAD) is a common disorder usually associated with silent or
symptomatic arterial disease elsewhere in the circulation and a “cluster” of cardiovascular …

Patients with peripheral arterial disease (PAD) are at very high risk of cardiovascular events,
but risk factor management is usually suboptimal. This Joint Task Force from the European …

Peripheral arterial disease (PAD) is a prevalent, chronic, and progressive atherosclerotic
disease process involving the conduit vessels of the extremities. Most patients who present …

(8, 9). Therefore, PAD should be treated to achieve the appropriate NCEP ATP III low-
density lipoprotein cholesterol (LDL-C) target of 70 to 100 mg/dL (1.8–2.6 mmol/L)(8, 9) …

Background Low-density lipoprotein cholesterol (LDL-C) is associated with heightened risk
of major adverse cardiovascular events (MACE) and major adverse limb events (MALE) in …

In the past 50 years, randomized clinical trials demonstrated benefits of intensive low-
density lipoprotein–lowering therapy for people with cardiovascular disease, including in …

Atherosclerotic peripheral artery disease (PAD) is a growing health issue that affects more
than 200 million individuals worldwide, conferring a high risk of cardiovascular events and …